Update on Long-Term Efficacy and Safety of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, Over 5 Years from an Ongoing Phase 2 Open-Label Extension
- Resource Type
- Abstract
- Source
- In
Multiple Sclerosis and Related Disorders December 2023 80 - Subject
- Language
- ISSN
- 2211-0348